PharmD Signal

Deep dives, evidence grades, and clinical tools, all in one place.

LinkedIn

Subcutaneous Natalizumab Cuts Chair Time, Cost, Boosts Quality of Life

This Italian time-and-motion study quantifies the operational, economic, and patient-experience advantages of subcutaneous over intravenous natalizumab, informing infusion-center workflow and formulary decisions for MS pharmacists.
natalizumabTysabrimonoclonal antibodyrelapsing-remitting multiple sclerosissubcutaneous administrationhealth economicstime-and-motion studyquality of lifeEASIER 2 Neurology / Neuropharmacology

Background Information

Subcutaneous natalizumab streamlines MS care while enhancing patient experience.

Improving administration methods for natalizumab in multiple sclerosis (MS) could enhance patient quality of life and reduce healthcare costs. Subcutaneous natalizumab reduced patient time in centers by 77%, healthcare professional time by 35%, and costs by up to 60%, with significant quality of life improvements. This study demonstrates the efficiency and effectiveness of subcutaneous versus intravenous delivery, potentially simplifying organizational demands in MS centers. Subcutaneous natalizumab significantly reduces procedure times and costs and improves patient quality of life.

📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report.
Subscribe for Full Access →

Authors: Filippi M, Grimaldi LME, Brescia Morra V, Conte A, Cordioli C, Totaro R, Lus G, Rini A, Marinelli F, Valentino P, Perini P, Marfia GA, Valente M, Malucchi S, Zanetta C, Pradelli L, Perini D, Santoni L, EASIER 2 study working Group

Citation: Filippi M, Grimaldi LME, Brescia Morra V, et al. Subcutaneous natalizumab administration in relapsing-remitting multiple sclerosis: results of EASIER 2 study. Journal of neurology. 2026;273(8). doi:10.1007/s00415-026-13977-w

Article Links: PubMed · Journal / DOI · Free Full Text (PMC)

🎓
Reviewed by a licensed pharmacist
Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.
Accurate and up-to-date information is our highest priority.
If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.
Suggest a correction Request a topic
🔒
Deep Analysis: Subscribers Only
Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.
Executive Summary
Study Design
Patient Population
Primary Outcomes
Secondary Outcomes & Safety Profile
Pharmacist Implications
Clinical Pearls
Limitations
Controversies & Evidence Gaps
Cost & Logistics
Want the full analysis?

Subscribe to PharmD Signal for unrestricted access to every deep analysis, plus PDF reports, GRADE evidence grades, and pharmacist implications for every article we publish.

Become a Subscriber →